At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA ...

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-010 trial investigating KEYTRUDA, ...

Keytruda plus chemotherapy did not negatively affect health-related quality of life in cervical cancer patients, regardless of Avastin addition. The KEYNOTE-826 trial involved 587 patients, assessing ...

Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo. Keytruda (pembrolizumab) in the ...

STRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and ...

Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology ...

Merck & Co Inc MRK announced topline data from the Phase 3 KEYNOTE-811 trial of Keytruda (pembrolizumab) plus trastuzumab and chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive ...

Merck's monoclonal antibody therapy Keytruda reduced the risk of early stage lung cancer progressing or death by 24% in patients who had undergone surgery, according to clinical trial data. The ...